Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma

F. Landoni, A. Maneo, A. Colombo, G. Cormio, F. Placa, S. Nava, R. Rossi, C. Mangioni

Research output: Contribution to journalArticlepeer-review


Despite innovative techniques in radiotherapy delivery no significant improvement in survival rates for cervical carcinoma has been achieved during the last few decades. Concurrent chemoradiation (CR) is one of the several avenues being explored to improve these results. Forty-seven women with locally advanced (IB2-IVA) squamous cell carcinoma of the uterine cervix were treated with CR, comprising a combination of external and intracavitary radiation along with three cycles of 5-FU and carboplatin. Treatment was well tolerated with 81% of the patients completing the CR protocol as planned. Acute toxicity was severe but manageable: 16 patients (34%) experienced grade 3-4 acute toxicity. Late morbidity occurred in 15% of the patients. Overall response rate was 88%. At a median follow-up time of 19 months (range 12-59) 62% of the patients are alive without disease and 18% are dead of disease. Actuarial two-year survival rate for the whole group of patients is 64%. Concomitant carboplatin/5-FU and radiotherapy is a safe and tolerable mean of treatment for locally advanced cervical cancer. The true advantage for survival, however, can be demonstrated only after completion of randomized trials comparing CR with conventional radiation therapy.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalInternational Journal of Gynecological Cancer
Issue number6
Publication statusPublished - 1997


  • 5-Fluorouracil
  • Carboplatin
  • Cervical carcinoma
  • Chemoradiation

ASJC Scopus subject areas

  • Cancer Research
  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Concurrent carboplatin/5-FU and radiotherapy for locally advanced cervical carcinoma'. Together they form a unique fingerprint.

Cite this